focus
Previous article:
FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article: What drug price negotiations mean for Medicare Part D
Next article: What drug price negotiations mean for Medicare Part D
focus
explore
-
Illumina names Agilent executive as new CEO
2025-09-30 17:22 -
How to bring more disabled researchers into academia
2025-09-30 16:28 -
A new House health package & hospitals’ new site
2025-09-30 16:13 -
With psoriasis trial ahead, Alumis raises $259 million
2025-09-30 15:58 -
The drug industry has found itself all alone in Washington
2025-09-30 15:47 -
Why Novartis is changing the name of its research labs
2025-09-30 15:31